Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$36.95 USD

36.95
1,964,098

+0.37 (1.01%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $36.96 +0.01 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Qiagen (QGEN) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

Bio-Techne Opens New Customer Experience Centre in Germany

by Zacks Equity Research

TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

Moumi Mondal headshot

HOLX Stock Down 24.7% in 6 Months: Time to Cut Losses or Buy the Dip?

by Moumi Mondal

As Hologic works through the changing macroeconomic and geopolitical landscape, its long-term potential makes it a solid hold.

Zacks Equity Research

Is it Worth Retaining QIAGEN Stock in Your Portfolio Now?

by Zacks Equity Research

QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.

Zacks Equity Research

Qiagen (QGEN) Down 6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

QGEN Stock Up on FDA Nod for Second QIAstat-Dx Gastrointestinal Panel

by Zacks Equity Research

QIAGEN wins the FDA's clearance for the second QIAstat-Dx mini gastrointestinal panel.

Moumi Mondal headshot

Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock?

by Moumi Mondal

HOLX's latest regulatory successes draw investors' attention. However, macroeconomic challenges restrict its full growth potential.

Zacks Equity Research

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

by Zacks Equity Research

QGEN's performance benefits from a resilient portfolio in the fourth quarter of 2024.